Multiple Sclerosis Summit on Infections and Immunizations in the Era of COVID-19
August 12th, 2021
Consortium of Multiple Sclerosis Centers (CMSC), Can Do MS, and NeurologyLive® Present Virtual Summit on August 24th for Healthcare Providers and People Living with MS
(Hackensack, NJ, August 12 )—The Consortium of Multiple Sclerosis Centers (CMSC) is partnering with Can Do Multiple Sclerosis and NeurologyLive to present a virtual MS Summit on August 24 at 7 pm ET, that addresses COVID-19, immunizations, and their implications for the MS population. The MS Summit is intended for healthcare providers, people living with MS, and their care partners. It will feature experts in the fields of immunology, virology, and neurology and address infections and MS – including the COVID-19 pandemic, general immunizations, as well as those specifically used for COVID-19.
Opening remarks for the MS Summit will be delivered by Kathy Costello, CRNP, Vice President of Programs, Can Do MS, followed by breakout sessions specifically for healthcare providers and patients and caregivers. The healthcare provider session will be led by Avindra Nath, MD, Intramural Clinical Director of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, and Amit Bar-Or, MD, FRCPC, Director of Neuroinflammation and Neurotherapeutics, Penn Medicine.
Topics covered will include how SARS-CoV-2 caused a global pandemic and the significance of the new variant. Immunizations, in general, and those specifically used for COVID-19, will be discussed in detail including the research process, mechanism of action, safety, and any implications for people with MS—including those on disease-modifying therapies—will be discussed. Recent National Multiple Sclerosis Society guidance on the use of vaccines in people with MS will be reviewed, including a risk-benefit discussion and thorough explanation using real-world scenarios so that providers are clear on the safety and use of the COVID-19 vaccines. Identifying interactions and risks of MS disease-modifying therapies and COVID-19 immunizations will also be explored.
“This important MS Summit will impart knowledge to healthcare professionals and confidence in providing guidance to patients around COVID-19 and vaccines,” said June Halper, CEO, CMSC.
“NeurologyLive prides itself on keeping neurology healthcare providers up-to-date on the latest guidance and research to help improve patient outcomes. As such, we are proud to partner with CMSC and Can Do Multiple Sclerosis on this important event to help better inform the MS community,” said Michael J. Hennessy Jr., President and Chief Executive Officer, MJH Life Sciences, parent company of NeurologyLive.
If you are a healthcare professional, a person with MS, or simply someone interested in learning more, tune in on August 24 at 7:00 pm ET. Register here for free.
About Consortium of Multiple Sclerosis Centers
The CMSC includes a professional network of 13,500 healthcare clinicians and scientists worldwide. Its membership represents the full spectrum of MS healthcare professionals: physicians, nursing professionals, advanced practice clinicians, pharmacists, rehabilitation and mental health professionals, researchers, and patient advocates. The work of the CMSC directly influences the quality of care for hundreds of thousands of people living with MS. For more information visit: www.mscare.org
A national nonprofit organization based in Avon, Colo., Can Do MS transforms lives by delivering health and wellness education programs on exercise, nutrition, symptom management, and motivation to help families living with MS thrive. Learn more at www.CanDo-MS.org.
A multimedia platform for health care professionals treating neurological diseases, NeurologyLive® delivers direct access to practice-changing news and expert insights directly from top medical conferences and researchers to improve the lives of patients with neurological diseases such as dementia and Alzheimer disease, epilepsy, headache and migraine, movement disorders, multiple sclerosis, neuromuscular diseases, sleep disorders, and stroke. The NeurologyLive® platform offers an in-depth look at the hundreds of new treatments in development with ever-expanding mechanisms of action, all during an unprecedented time of growing demand for neurology expertise. The NeurologyLive® platform also connects visitors with the most up-to-date clinical trial results, Food and Drug Administration approvals, practice-changing research, and expert insights. NeurologyLive® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.